Burgess SV, Hussaini T, Yoshida EM

Language: English
References: 22
Page: 154-159
PDF size: 137.55 Kb.

ABSTRACT

The goal of treatment for chronic hepatitis C viral (HCV) infection is to cure the infection rather than suppress the virus. Historically, a sustained virological response (SVR) defined as undetectable HCV RNA at 24 weeks following the completion of treatment was considered the gold standard to define successful eradication of the virus as a primary endpoint in clinical trials. SVR measured at 12 weeks post-treatment has been shown to be highly concordant with SVR24 in trials of pegylated interferon and ribavirin. The appropriateness and durability of SVR12 as the efficacy endpoint with new oral direct-acting antivirals is less established. A literature search was performed using PubMed, EMBASE and CENTRAL databases to identify any studies that examined the concordance between SVR24 and earlier time points. Two studies and 4 abstracts were found that performed concordance analyses using positive and negative predictive values. Overall, SVR4 and SVR12 were highly concordant with SVR24 with high positive (› 97%) and negative (› 94%) predictive values; however there was a higher risk of HCV relapse occurring after post-treatment week 4. The majority of the data focused on SVR12 and demonstrated that SVR12 reliably predicted SVR24 in several populations infected with HCV (treatment-naïve, prior null responders, different genotypes) using various new oral direct-acting antiviral regimens. In conclusion, the available data suggests that SVR12 is a reliable assessment of HCV eradication and could be used instead of SVR24 for drug development clinical trials assessing efficacy of new direct-acting antivirals. Data on the long-term durability of SVR12 is still needed.

REFERENCES

1. MohdHanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42.

2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-128.

3. Diagnosis, management, and treatment of hepatitis C: An update. AASLD Practice Guidelines.Hepatology 2009; 49: 1335-74.

4. US Food and Drug Administration Guidance for Industry Chronic Hepatitis C Virus Infection: Developing Direct- Acting Antiviral Drugs for Treatment 2013; October. Available at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/ guidances/ucm225333.pdf

5. Van der Meer A, Veldt B, Feld J, Wedemeyer H, Dufour J. Association between sustained virological response and allcause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.

6. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: A cure and so much more. Clin Infect Dis 2011; 52: 889-900.

7. Maylin S, Martinot-Peignoux M, Ripault M-P, Moucari R, Cardoso AC, Boyer N, Giuily N, et al. Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody. Liver Int 2009; 29: 511-7.

8. Swain MG, Lai M, Shiffman ML, Cooksley WGE, Zeuzem S, Dieterich DT, Abergel A, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon Alfa-2a and ribavirin. Gastroenterology 2010; 139: 1593-601.

9. Martinot-Peignoux M, Stern C, Maylin S, Ripault MP, Boyer N, Leclere L, Castelneu C, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis c virus receiving pegylated interferon and ribavirin. Hepatology 2010; 51: 1122-6.

10. Chen J, Florian J, Carter W, Fleischer RD, Hammerstrom TS, Jadhav PR, Zeng W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013; 144: 1450-5.e2.

11. Zeuzem S, Heathcote EJ, Shiffman ML, Wright TL, Bain VG, Sherman M, Feinman V, et al. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon α for chronic hepatitis C. J Hepatol 2003; 39: 106-11.

12. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. Available from: http:// www.hcvguidelines.org[cited 2015, Sep 1].

13. Manns MP, von Hahn T. Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov Nature Publishing Group 2013; 12: 595-610.

14. Poordad F, Agarwal K, Younes Z, Cohen D, Xie W, Podsadecki T. Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infect. Clin Infect Dis 2014; 60: 608-10.

15. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, et al. Phase 2b trial of interferonfree therapy for hepatitis C virus genotype 1. N Engl J Med2014; 370: 222-32.

16. Yoshida EM, Sulkowski MS, Gane EJ, Herring RW, Ratziu V, Ding X, Wang J, et al. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir- containing regimens for hepatitis C virus.Hepatology 2015; 61: 41-5.

17. Bernstein D, Mangia A, Brau N, Yang J, Ma J, Hyland R, Pang P, et al. Concordance between SVR4, SVR12 and SVR24 in genotype 1 HCV-infected patients who received all oral fixed-dose combination ledipasvir/sofosbuvir with or without ribavirin in phase 3 clinical trials [Abstract 1947] 2014 AASLD Conference. Hepatology 2014; 1142-3.

18. Lawitz E, Gane EJ, Lalezari J, Hyland RH, Ma J, Symonds WT, Hassanein T, et al. High concordance of SVR4, SVR12, and SVR24 in patients with HCV infection who have received treatment with sofosbuvir [Abstract 848]. J Hepatol 2013; 58: S348.

19. Lawitz E, Hezode C, Varunok P, Thuluvath P, Baykal T, Kapoor M, Lovell S, et al. Concordance of SVR12 with SVR4 and SVR24 in patients with chronic HCV genotype 1b treated with the interferon- and ribavirin-free ABT-450/r and ABT-267 regimen. [Abstract] 23rd Conference of the Asian Pacific Association for the Study of the Liver; March 12-15, 2014.

20. Lawitz W, Hezode C, Varunok P, Thuluvath P, Baykal T, Kapoor M, Lovell S, et al. Interferon-and ribavirin-free regimen of ABT-450/r + ABT-267 in HCV genotype 1b-infected treatment- naïve patients and prior null responders: PEARL-I. [Abstract] 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013.

21. Zeuzem S, Soriano V, Asselah T, Bronowicki J, Lohse A, Mullhaupt B, Schuchmann M, et al. SOUND-C2: SVR4, 12, and 24 concordance in genotype (GT) 1 HCV patients receiving interferon (IFN)-free treatment with the HCV NS3/4A protease inhibitor BI 201335 and the NS5B polymerase inhibitor BI 207127. [Abstract] 63rd Annual Meeting of the American Association for the Study of Liver Diseases. Hepatology 2012; 569A.

22. Cheng W, Shafran S, Beavers K, Mo H, McNally J, Brainard D, et al. Long term follow-up of patients treated with sofosbuvir in the FISSION, POSITRON, FUSION and NEUTRINO phase 3 studies. 49th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress 2014 London United Kingdom. J Hepatol 2014; S449.